EW - Utang jangka dawa perusahaan Edwards Lifesciences Corp

An aging population is driving increased demand for minimally invasive cardiology. The long-term financial debt of Edwards Lifesciences (EW) demonstrates business stability, while 0.63 reflects the latest value of the metric. The dominance of Edwards Lifesciences (EW) in the transcatheter valve segment ensures a technological lead, which is further bolstered by the implementation of ESG environmental standards and strict quality control in implant production.

Investors view Edwards Lifesciences (EW) as a technological leader in the cardiac surgery segment with high barriers to entry. This indicator captures the total credit obligations with maturities exceeding one year, determining the long-term financial burden. By analyzing the issuer's long-term liabilities, one can track the scale of borrowing used to fund costly R&D developments. A rational debt balance confirms the sustainability of the strategy to capture the transcatheter solutions market.